IP Pharma (IPP) offers professional advisory services to Pharmaceutical, Biotechnology, Medical Device and Healthcare Service companies. On behalf of its clients, it specialises in searching for and valuing products for acquisition or divestment and bringing buyers and sellers together.
IPP offers confidential search and tailored advice to organisations that are looking to acquire assets across the whole spectrum of the product life-cycle, ranging from pre-marketed candidates to Rx to Gx to OTC/CHC licenced medicines.
As an organisation, we have up to date information that enables IPP to match products that have been marked for divestment by their owners to the needs of potential acquirers. We can routinely match acquirer requirements with potential products for sale.
Over the last decade IP Pharma has had the privilege of working with leading industry clients across big pharma, midcaps and start-ups, private equity funds and investment banks.
Based on experience and research, IP Pharma is able to advise clients on asset valuations and deal structuring with the aim of creating win-win scenarios for both the buyer and seller resulting in the timely closing of transactions/deals.
IP Pharma is able to work with clients and investors such as private equity and hedge funds and investment banks who wish to identify and create experienced teams that can manage and operationalize asset acquisitions within newco’s.
IPP is experienced in and able to guide and offer its clients advice and support throughout the process of deal negotiation to full completion.
In-order for our clients to grow faster on a global basis or to aid their research capabilities, IP Pharma can be engaged to deliver short or long term outsourced business development activities across all asset types and therapy areas.
IPP can both work with deal teams and manage and deliver comprehensive deal related due diligence activities in areas such as financial, commercial, manufacturing and supply, legal, marketing, regulatory and Medical information and pharmacovigilance.